A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
about
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerEverolimus in the Treatment of Metastatic Breast CancerPotentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesEfficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.The therapeutic potential of mTOR inhibitors in breast cancer.Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.Metastatic breast cancer: Endocrine therapy landscape reshaped.Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.Kinase-targeted cancer therapies: progress, challenges and future directions.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.Endocrine Resistance in Breast Cancer
P2860
Q26770482-EF9BD787-BEE1-4B1F-AE9D-1E1A046B98E6Q26775361-7A7E7EEB-49B5-4172-B6B2-0FAB39FC6FDFQ26784920-7567B9E2-684B-4A08-A77F-520D2C48C122Q28546221-D9A4DE38-413A-4A2C-86C9-5AC05F69CD7EQ33441090-1DEA2716-7108-4C2B-AA5A-E556A4777E6CQ33903949-795A12EE-D14A-42B3-9090-23413B166093Q34103963-29348D3C-E58C-4A32-827D-B9FAFDAFD2F8Q36861416-3B820B38-18A7-4787-B1FF-B8380FFE9E99Q36933778-70F01C1B-C487-4291-9AD5-133ABBEBAEF1Q37074917-4E455706-BDA8-4663-8FD5-638C825B92BAQ37570653-97021AB2-96CF-4200-A91E-3A1E945B0AEDQ38802412-FDDAD19B-31CB-4B9E-B9EC-43A93C74469CQ39192955-A70DCEEE-C160-4505-A717-526FC4D6933EQ40989080-F4F8817E-DC60-42FF-B90B-41A8491EFE67Q42755954-0FC0BBC6-0549-4AF7-AB61-D7B164F29DA8Q45072397-D682A330-1437-4B97-9602-06094ED75E63Q47101508-FE69198F-D861-4FE6-97DB-9F8E9F9F66F9Q49887882-D8EAF308-6D7E-4FFD-A23A-55F55271D6F8Q54349937-058E74FF-85DC-4EAA-BD41-635B354BAB25Q59072640-560F1B82-A8E1-4057-BFE2-1986E29FE29A
P2860
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase II study of combined f ...... matase inhibitor (AI) failure.
@en
A phase II study of combined f ...... h metastatic estrogen receptor
@nl
type
label
A phase II study of combined f ...... matase inhibitor (AI) failure.
@en
A phase II study of combined f ...... h metastatic estrogen receptor
@nl
prefLabel
A phase II study of combined f ...... matase inhibitor (AI) failure.
@en
A phase II study of combined f ...... h metastatic estrogen receptor
@nl
P2093
P2860
P1476
A phase II study of combined f ...... matase inhibitor (AI) failure.
@en
P2093
Brent Shelton
Edward Romond
Esther P Black
Mark Stevens
Richard Elledge
Suleiman Massarweh
Vera Kadamyan-Melkumian
P2860
P2888
P304
P356
10.1007/S10549-013-2810-9
P407
P577
2013-12-11T00:00:00Z